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Development of cardiac allograft vasculopathy represents 
the major determinant of long-term survival in patients af-
ter heart transplantation. Due to graft denervation, these 
patients seldom present with classic symptoms of angina 
pectoris, and the first clinical presentations are progres-
sive heart failure or sudden cardiac death. Although coro-
nary angiography remains the routine technique for coro-
nary artery disease detection, it is not sensitive enough for 
screening purposes. This is especially the case in the first 
year after transplantation when diffuse and concentric vas-
cular changes can be easily detected only by intravascular 
ultrasound. The treatment of the established vasculopathy 
is disappointing, so the primary effort should be directed 
toward early prevention and diagnosis. Due to diffuse vas-
cular changes, revascularization procedures are restricted 
only to a relatively small proportion of patients with favora-
ble coronary anatomy. Percutaneous coronary intervention 
is preferred over surgical revascularization since it leads to 
better acute results and patient survival. Although there is 
no proven long-term advantage of drug-eluting stents for 
the treatment of in-stent restenosis, they are preferred over 
bare-metal stents. Severe vasculopathy has a poor progno-
sis and the only definitive treatment is retransplantation. 
This article reviews the present knowledge on the patho-
genesis, diagnosis, treatment, and prognosis of cardiac al-
lograft vasculopathy.
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The leading causes of death during the first three years after 
heart transplantation are nonspecific graft failure and infec-
tions. Nonspecific graft failure may be caused by chronic 
graft rejection, while acute graft rejection accounts for no 
more than 11% of mortality. The major determinants of 
patient survival after three years are malignancy and car-
diac allograft vasculopathy (CAV), also known as transplant 
coronary artery disease or cardiac transplant vasculopathy. 
It is detected by coronary angiography in 8% of patients 
by year 1, 30% by year 5, and 50% by year 10 after trans-
plantation (1). Due to graft denervation, CAV typically de-
velops without the warning symptoms of angina pectoris 
and manifests with symptoms of graft failure, arrhythmias, 
or even sudden cardiac death. Patients may present with 
atypical symptoms such as exertional dyspnea, gastrointes-
tinal distress, diaphoresis, or syncope. It is not unusual that 
CAV is diagnosed after an incidental finding of Q-waves on 
ECG or loss of contractile function on a routine echocardio-
graphic exam (2). The vasculopathic lesions in the proximal 
coronary segments are more focal and eccentric, while the 
mid and distal coronary segments are affected in a more 
diffuse and concentric pattern, with typical vessel prun-
ing (Figure 1) (3). Proximal disease is donor-inherited and 
atherosclerotic in nature, while the mid- and distal disease 
is more immune-mediated and recipient-acquired. CAV is 
characterized by diffuse concentric intimal hyperplasia, ie, 
thickening of the epicardial arteries and concentric medial 
disease in the coronary microcirculation with the constric-
tion of the external elastic membrane area and lumen loss 
(4). Unnoticed by coronary angiography, the most of the 
intimal thickening occurs during the first post-transplant 
year (5). The disease progression is often complicated by in-
tracoronary thrombosis and subsequent, often silent, acute 
myocardial infarction (Figure 2) (6). Early mural thrombi 
primarily contain platelets, while succeeding thrombi are 
more organized, usually occlusive and primarily consist of 
fibrin (7). Development and progression of CAV in trans-
plant patients is strongly associated with enhanced platelet 
activation, although no evidence supports the benefit from 
aspirin therapy in these patients (8,9).
To create uniform definition and enable staging of trans-
plant vasculopathy, the International Society of Heart and 
Lung Transplantation (ISHLT) proposed a grading system 
based on the combination of angiographic finding and graft 
function defined either by ultrasound or invasive hemody-
namic measurement (10): CAV
0 (no detectable angiograph-
ic lesions) = no vasculopathy; CAV1 (mild disease) = left main 
stenosis <50% or primary vessel stenosis <70% (including 
right coronary artery – RCA) or any branch stenosis <70%, 
without graft dysfunction; CAV2 (moderate disease) = left 
main stenosis <50% or single primary vessel stenosis >70% 
or isolated branch stenosis >70% in 2 systems, without 
graft dysfunction; CAV3 (severe disease) = left main steno-
sis ≥50% or stenosis >70% in two or more primary vessels 
or isolated branch stenosis >70% in three systems; or ISHLT 
CAV1 or ISHLT CAV2 with signs of graft dysfunction. Allograft 
dysfunction is defined as left ventricular ejection fraction 
≤45% or evidence of significant restrictive pathology either 
FIGure 1. Diffuse stenosis of the left anterior descending 
artery and distal pruning of left circumflex artery in a patient 6 
years after heart transplantation.
FIGure 2. Acute thrombotic occlusion of the right coronary 
artery manifested as ventricular fibrillation and cardiac arrest 
in a patient 2 years after heart transplantation.
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on echocardiographic exam (E/A ratio >2, isovolumetric re-
laxation time <60 ms, deceleration time <150 ms) or right 
heart catheterization (right atrial pressure >12 mm Hg, pul-
monary capillary wedge pressure >25 mm Hg, cardiac index 
<2 L/min/m2). In this nomenclature, primary vessels stand 
for the proximal and middle thirds of the left anterior de-
scending artery, the left circumflex, the ramus intermedius, 
and the dominant or co-dominant RCA. Branch vessels de-
note distal thirds of the primary vessels or large septal, diag-
onal, and obtuse marginal branch or any portion of a non-
dominant RCA (10). CAV is present in 44% of our patients 
at 5 years after transplantation with the proportion of CAV1, 
CAV2, and CAV3 of 50%, 32%, and 18%, respectively.
PAtHoGeneSIS
CAV development is related to numerous immunologic 
and non-immunologic factors. The immunologic factors 
seem to be of crucial importance since vasculopathy de-
velops in the donor’s rather than in the recipient’s vessels. 
The role of inflammation is congruent with the observa-
tion that the increased C-reactive protein (CRP) is a strong 
predictor of CAV development after heart transplantation 
(11). Multiple immunologic mechanisms triggering coro-
nary vessel injury are initialized after the host’s immune 
system recognizes non-self histocompatibility antigens 
(HLA) of the transplanted heart in the process of allorec-
ognition. This is followed by T-cell activation, formation of 
donor specific antibodies, endothelial cell activation, and 
altered cytokine expression (12). Recipients who develop 
CAV show a greater incidence of HLA mismatching, while 
the HLA-DR mismatching best predicts an adverse out-
come (13,14). The majority of trials found the risk of CAV to 
be related to the number of moderate and severe cellular 
rejection episodes, as well as to the total rejection score, 
which represents the summary of overall rejection (15-17). 
Antibody-mediated rejection, also known as humoral or 
vascular rejection, is characterized by anti-HLA and anti-
endothelial antibodies formation, and it is also related to 
CAV development (18,19). The presence of anti-endothe-
lial antibodies correlates strongly with the progression of 
vasculopathy (72% vs 5% in patients without antibodies) 
and the presence of anti-HLA antibodies with considerably 
lower 4-year survival (90% vs 38%) (20,21).
The graft endothelium represents the borderline between 
the donor’s and recipient’s immune systems and plays a 
critical role in the pathophysiology of CAV. The increased 
expression of major histocompatibility complex (MHC) 
class I alloantigens on coronary endothelial cells of 
the transplant heart are directly recognized by CD8+ T-
cells, resulting in the secretion of cytokines with further ac-
tivation of endothelial cells. The activated endothelial cells 
express increased levels of MHC class II antigens, which 
later activate CD4+ T-cells. This can explain the predomi-
nance of CD8+ T-cells in the early vasculopathic lesions and 
the increased proportion of CD4+ T-cells in the advanced 
stage of the disease (22). Endothelial activation is the ini-
tial step of immune response propagation, followed by re-
cruitment of pro-inflammatory cells from the vessel wall. 
This is accompanied by marked expression of the intercel-
lular cell adhesion molecule-1 (ICAM-1), vascular cell adhe-
sion molecule-1 (VCAM-1), and P-selectin on the surface 
of allograft endothelial cells – a phenomenon also seen in 
the acute cellular rejection (23-25). In fact, endothelial ac-
tivation during the first months following heart transplan-
tation predicts future graft vasculopathy (26). Increased 
serum level of soluble ICAM-1 correlates with the level of 
endothelial ICAM-1 in the biopsy specimens and predicts 
both CAV development and graft failure (27). Endothelial 
activation results in endothelial dysfunction, which may 
be detected as abnormal coronary vasomotor response to 
acetylcholine or adenosine on angiography (28).
Multiple cytokines with proliferative effects on coronary 
smooth muscle cells have been detected within vasculo-
pathic lesions: interleukin-1 (IL-1), interleukin-6 (IL-6), tumor 
necrosis factor-alpha (TNF-α), platelet derived growth fac-
tor, insulin-like growth factor-I, macrophage chemoattrac-
tant protein-1 (MCP-1), fibroblastic growth factor, vascular 
endothelial growth factor, transforming growth factor-al-
pha, and TGF-beta-1 (29-34). Interferon-gamma (IFN-gam-
ma) is secreted by T-cells and performs a variety of actions: 
activates macrophages, enhances the expression of MHC 
antigens and other components of the antigen presenta-
tion pathway as well as the adhesion molecules ICAM-1 
and VCAM-1. The deficit of IFN-gamma was found to pro-
tect mice from transplant vasculopathy (35), while some 
genetic polymorphisms of TNF-α and IL-6 have been relat-
ed to CAV development (36,37).
Non-immunologic factors associated with increased risk of 
CAV include age, sex, recipient body mass, diabetes mel-
litus, smoking, dyslipidemia, donor history of arterial hy-
pertension, recipient history of previous coronary artery 
disease, cytomegalovirus (CMV) infections, defective fibrin-
olysis, polymorphism in angiotensin converting enzyme 
gene, early graft dysfunction due to preservation damage, 
ischemia-reperfusion injury, as well as the etiology of brain 
death of the donor (38). Non-immunologic factors cause 
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endothelial dysfunction and damage, as well as promote 
the activation of the coagulation pathway. They also initi-
ate nonspecific vascular inflammation, which induces the 
expression of endothelium-derived MHC antigens and 
promotes traveling of dendritic cells into the allograft, re-
sulting in increased graft immunogenicity and recipient al-
loimmune response.
While older age and male sex of the donors are associat-
ed with higher risk, older age of the recipient is associated 
with lower risk for CAV (14,38,39). CAV severity correlates 
with the increase in total serum cholesterol, low-density li-
poprotein (LDL)-cholesterol, oxidized LDL-cholesterol, and 
triglycerides, which are common metabolic abnormalities 
after heart transplantation due to use of corticosteroids 
and cyclosporine, and obesity (40,41). Lipid-lowering treat-
ment with statins is one of the few therapeutic approaches 
able to reduce both the development and progression of 
allograft vasculopathy (42).
The relation between CAV development and CMV infec-
tion can be explained by stimulation of immune response 
in the vessel wall via induced expression of endothelial 
MHC antigens and direct endothelial damage resulting in 
dysregulation of the NO pathway, activation of coagula-
tion cascade, cytokine secretion, and vascular remodeling 
with vessel lumen loss (43,44).
Glucose intolerance and insulin resistance are associat-
ed with higher likelihood of CAV and increased mortality 
(45,46). Metabolic syndrome, characterized by abdominal 
obesity, hypertension, diabetes, and dyslipidemia (hyper-
triglyceridemia and low HDL-cholesterol) is frequently ob-
served in transplant patients. The combination of high CRP 
and insulin resistance, defined as triglyceride to HDL ratio 
>3.0, synergistically causes a 4-fold increase in CAV risk (47). 
Allograft vasculopathy is more likely to occur if either the 
recipient or the donor have the history of coronary artery 
disease (39,48). The risk for CAV may also be increased by 
impaired fibrinolytic system with procoagulant microcircu-
lation and depletion of tissue-type plasminogen activator 
(tPA) from the arteriolar wall (49). Local tPA depletion may 
be due to genotype-specific overexpression of plasmino-
gen activator inhibitor-1 (PAI-1), with the donor 2/2 geno-
type associated with an increased risk of CAV (50,51). Graft 
vasculopathy is also related to the depletion of vascular an-
tithrombin (52).
The paradoxical constriction of coronary arteries in re-
sponse to acetylcholine is a sign of endothelial dysfunc-
tion and is predictive of vasculopathy (53,54), while the up-
regulation of inducible nitric oxide synthase and increased 
expression of heat shock protein 27 seem to play protec-
tive roles (55,56). CAV development is also associated with 
the DD genotype of angiotensin converting enzyme gene 
polymorphism (57). The up-regulation of endothelin-1 in 
the coronary vessels contributes to vasculopathic chang-
es by vasoconstriction, as well as by proliferation of intima 
and media (58). Endothelial injury may accompany myo-
cardial damage that occurs with the brain death of the 
donor, suboptimal myocardial preservation, and ischemia-
reperfusion graft injury following transplantation. This in-
jury may be detected as early graft failure with high risk of 
future graft vasculopathy (59). The systemic activation of 
matrix metalloproteinase-2 is detected in donors after ex-
plosive brain death (ie, head trauma, intracerebral hemor-
rhage, gunshot wound), which is also related to CAV (60). 
Other factors that were associated with an increased risk 
of CAV include recipient obesity, recipient ischemic cardi-
omyopathy (vs non-ischemic cardiomyopathy), increased 
myocardial elastase activity, hepatitis C virus seropositivity, 
and increased blood levels of homocysteine or von Wille-
brand factor (38,61-64).
The complex interactions between the immunologic and 
non-immunologic factors cause endothelial damage with 
consequent endothelial activation and dysfunction. En-
dothelial activation stimulates expression of adhesion 
molecules and cytokine secretion, which further promote 
cell invasion, smooth muscle cells growth, and vascular 
matrix deposition, finally resulting in typical morphologi-
cal vascular changes. Derangement of endothelial repair 
mechanism in transplant patients may also play a role. The 
level of circulating human endothelial progenitor cells 
(EPCs) was found to be significantly decreased in patients 
with CAV compared with matched patients without evi-
dence of the disease. This may be explained by increased 
consumption of circulating pool of EPCs at the sites of 
graft endothelial injury. However, mobilization and sur-
vival of circulating EPCs was found to be suppressed by 
inflammation (65).
DIAGnoSIS
Due to the graft denervation, CAV will unlikely be diag-
nosed based on typical symptoms of angina pectoris. 
However, it should be suspected during routine echocar-
diographic examination if signs of graft dysfunction, such 
as regional wall abnormalities and/or restrictive diastol-
ic dysfunction, are found. When it becomes symp-
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tomatic, CAV is usually at an advanced stage and myocar-
dial damage is irreversible. For this reason, it is necessary to 
perform screening measures to improve early diagnosis.
Invasive screening methods include coronary angiogra-
phy and intravascular ultrasound (IVUS). They cause some 
discomfort to the patient, involve the risk of renal damage 
from contrast agent application, and are resource con-
suming. Other methods include analysis of microvascular 
changes on routine endomyocardial biopsies and nonin-
vasive methods like stress echocardiography, CT coronary 
angiography and measurement of serum biomarkers.
Coronary angiography is used to establish the diagnosis of 
CAV in most transplant centers. Depending on the center, 
the baseline angiography is commonly performed several 
weeks after the transplantation, while the following ones 
are performed annually or biannually. In our center, it is 
routinely performed biannually. However, coronary an-
giography is performed annually or even more frequently 
after the diagnosis of CAV has been established or if there 
are signs of new-onset graft dysfunction on echocardio-
graphic exam. Coronary angiography can identify luminal 
narrowing as well as slow contrast filling of the distal cor-
onary vessels, suggesting the involvement of small coro-
nary vessels and microcirculation. As coronary spasm may 
mimic concentric vessel narrowing in vasculopathy, intra-
coronary nitroglycerine should be applied before contrast 
injection in order to avoid false CAV diagnosis. Although 
angiography remains the routine technique for coronary 
artery disease detection, it is not sensitive enough for CAV 
detection due to diffuse, longitudinal, and concentric vas-
cular changes. The positive predictive power of coronary 
angiography compared to IVUS as the gold standard is 
only 44% (66). Consequently, transplant vasculopathy of-
ten remains angiographically undiagnosed at the early 
stage. Moreover, there is notable interobserver variation 
of angiographic diagnosis and the experience in this field 
of invasive cardiology is needed (67). Additionally, angiog-
raphy may help to diagnose CAV by the measurement of 
TIMI (thrombolysis in myocardial infarction) frame count, 
ie, the number of cine frames required for the contrast to 
reach distal coronary segments. The increase in TIMI frame 
count was observed in patients who eventually developed 
angiographically confirmed CAV after five years of follow-
up, although conflicting results were observed when TIMI 
frame count was correlated with IVUS finding (68). Coro-
nary flow reserve (CFR) measures the increase in coro-
nary blood flow in response to a vasodilator such as 
adenosine. The reduction of CFR may indicate the 
development of graft vasculopathy before angiographic 
changes occur (69).
Unlike angiography, IVUS can detect the abnormal con-
centric intimal thickening and is the most sensitive tool for 
CAV detection. The most rapid rate of intimal thickening 
occurs during the first posttransplant year (70). An increase 
in maximal intimal thickness (MIT) for ≥0.5 mm during that 
period indicates rapidly progressive CAV (71,72). Because 
of high positive predictive value, IVUS has been used as 
surrogate end-point in large multicenter clinical studies 
of drugs for the prevention and treatment of CAV. Disad-
vantages of IVUS include additional procedural risk, more 
time consumption, limited availability, and increased costs. 
However, IVUS is of crucial clinical importance in patients 
with unexplained graft failure, ie, those with normal coro-
nary angiography and no detectable rejection.
Noninvasive tests include conventional electrocardiogram 
stress test, dobutamine stress echocardiography, coro-
nary flow reserve (CFR) assessment by contrast-enhanced 
echocardiography, stress myocardial perfusion scintigra-
phy, positron emission tomography (PET) scanning, com-
puted tomography (CT) angiography as well as serum 
biomarkers testing. These studies are less sensitive, but as 
they are not invasive and are generally less expensive, may 
serve as adjunctive methods of screening for myocardial 
ischemia (73). The best-validated noninvasive method is 
dobutamine stress echocardiography, with the sensitivity 
of 85% as compared to angiography and IVUS. Further-
more, its negative predictive value is outstanding, ie, pa-
tients with normal stress study were shown to be free of 
adverse events (74,75). Noninvasive screening is used for 
low-risk transplant patients, ie, those with previously nor-
mal angiography, no signs of graft dysfunction, and a time 
span of more then five years after transplantation. It is also 
used in patients with advanced renal failure when it is de-
sirable to avoid the administration of contrast media. How-
ever, symptomatic patients or those with noninvasive tests 
results suggestive of CAV should be referred to coronary 
angiography or/and IVUS.
Contrast enhanced CFR has been evaluated by clinical 
studies as a method of screening, but it requires high-
quality imaging that is often impossible to perform due 
to unfavorable acoustic window in transplanted patients 
(76). Although CT coronary angiography has a sensitivity 
between 85%-100%, it suffers from many drawbacks such 
as poor image quality, tachycardia, which is typically pres-
ent in heart transplant patients, high burden of radiation, 
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nephrotoxicity since a greater amount of contrast is re-
quired than in conventional angiography, and the prob-
lem of small vessel disease detection (77,78). CT coronary 
angiography is at present not recommended for routine 
CAV monitoring.
Biomarkers like CRP or N-terminal pro-brain natriuretic 
peptide (NT-proBNP) were predictive of mortality but not 
of CAV development (79). Serum NT-proBNP level <800 
pg/mL was associated with better survival after transplan-
tation (80). Higher serum level of von Willebrand factor was 
a predictor of allograft vasculopathy (64).
Immunohistochemistry evidence of endothelial activation 
in the arteries and arterioles of endomyocardial specimens 
taken during the first three months after transplantation 
precede morphological changes in vasculopathy (26). 
Stenotic changes of the coronary microcirculation in the 
biopsy sample may also accompany epicardial vasculopa-
thy (81,82). The sensitivity of this method is low, but the 
positive finding highly predicts both CAV and death (83).
ProGnoSIS
CAV is a slowly progressive disease, though it may progress 
rapidly and result in graft failure, arrhythmias, or sudden 
cardiac death (SCD). Because of heart denervation, graft 
ischemia usually progresses without classic symptoms and 
SCD may be the first manifestation of vasculopathy. SCD 
may be prevented by cardioverter defibrillator implanta-
tion, though not entirely, as some of these deaths result 
from instantaneous and fatal heart failure (84). Significant 
prognostic factors for SCD are the presence of >25% cor-
onary stenosis on angiography or the worsening of TIMI 
frame count after the first year of follow-up (85,86). An in-
crease in maximal intimal thickness (MIT) on IVUS for ≥0.5 
mm indicates rapidly progressive CAV and is associated 
with more deaths and/or graft losses at 5-year follow-up 
(20.8% vs 5.9% in patients with <0.5 mm) (71). The com-
bined end-point of death and myocardial infarction was 
reached by 51% of patients with MIT increase of ≥0.5 mm 
vs 16% in patients with <0.5 mm MIT increase (72). The 
majority of epidemiological reports on the prevalence of 
CAV did not take into consideration the severity of this dis-
ease, which carries different prognostic risk. Costanzo et 
al (87) reported 42% CAV prevalence in the overall trans-
plant population after 5 years. However, only 7% of pa-
tients had severe CAV defined as left main stenosis >70% 
or >70% stenosis in two or more primary coronary arter-
ies or branch stenosis for >70% in all three coronary sys-
tems. Notably, the adverse outcome, including death and 
retransplantation, occurred in only 7% of the total number 
of CAV patients and even in two-thirds of patients with se-
vere vasculopathy (87). It seems that late-onset graft vas-
culopathy is an unusual disorder and that its incidence is 
significantly lower in patients who survived more than ten 
years after transplantation (88). Despite the lack of substan-
tial progress in CAV treatment, there was an increase in the 
survival of patients who were transplanted between 2001 
and 2007 compared to those transplanted between 1994 
and 2000 (89).
PreventIon
Because CAV has substantially poor prognosis when it be-
comes symptomatic, the primary effort is directed to early 
prevention, detection, and initiation of treatment. Only two 
types of drugs were found to provide significant protec-
tion from CAV: statins and mammalian target of rapamycin 
(mTOR) inhibitors.
Statins are considered mandatory in transplant patients 
because they improve patient survival, reduce both the in-
cidence and severity of vasculopathy, as well as the inci-
dence of graft rejection (90). They are typically instituted by 
the end of the first week or during the second week after 
heart transplantation. Pravastatin is started with 20 mg/d 
and then increased to 40 mg/d if tolerated (42). Simvasta-
tin is started with 5 mg/d and increased to 10 and 20 mg/d 
(91). The early initiation of statins is of utmost importance, 
as their later introduction in transplant patients did not 
have a favorable effect on graft prognosis although it re-
duced serum cholesterol level (92). The favorable effects of 
statins, besides lowering plasma lipids, may be explained 
with anti-inflammatory activity, cytokine suppression, and 
improvement of endothelial function (93,94). In our center 
we also use fluvastatin, atorvastatin, or rosuvastatin. Spe-
cial caution must be taken to avoid rhabdomyolysis, as 
most statins use CYP3A4 pathway that is already inhibited 
by calcineurin inhibitors (CNI). The risk is lower with fluvas-
tatin as it is metabolized by CYP2C9, and with pravastatin, 
as it is excreted largely unchanged (95).
Sirolimus (SRL) and everolimus (EVL), also known as mTOR 
or proliferation signal inhibitors (PSI), inhibit T-cell and B-
cell proliferation driven mainly by interleukins. Eisen et al 
showed superiority of EVL over azathioprine for the pre-
vention of CAV in de novo heart transplant patients al-
ready on cyclosporine and corticosteroid therapy (96). 
After 12 months, the patients on EVL had significant-
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ly slower progression of MIT as determined by IVUS. EVL 
was associated with lower incidence of graft rejection and 
CMV infection, but also with more frequent renal failure, 
bacterial infections, dyslipidemia, and thrombocytopenia. 
The beneficial effect of EVL on MIT was maintained for 2 
years of follow-up. Moreover, this treatment was associat-
ed with significantly fewer CAV-related events and revas-
cularization during 4 years of follow-up (97).
SRL in de novo heart transplant patients treated with cy-
closporine and corticosteroids reduced both MIT and 
≥3A rejection grade in comparison to azathioprine (98). 
Disadvantages of SRL included renal insufficiency, abnor-
mal wound healing, epistaxis, hyperlipidemia, anemia, 
and thrombocytopenia. In the early postoperative phase, 
SRL has been avoided due to the problem of slow wound 
healing in renal transplantation trials. Since the cause 
of renal function deterioration seems to lie in combina-
tion of mTOR inhibitors and calcineurin-inhibitor, a solu-
tion would be to reduce calcineurin-inhibitor concentra-
tions (99). Mycophenolate mofetil (MMF) in higher dosage 
(2 × 1.5 g/d) reduced minimal intimal thickness on IVUS 
in comparison to azathioprine during 3 years of follow-
up (0.06 vs 0.13 mm with azathioprine, P = 0.056). It also 
showed significantly lower incidence of retransplantation 
or death (100).
Diltiazem was shown to have benefits in a trial from the 
pre-statin era, which is not considered very strong evi-
dence, especially since this trial used quantitative coro-
nary angiography rather than IVUS (101). A later study in 
patients treated with statins found no benefits of diltiazem 
(102). Fang et al showed a favorable effect of antioxidant 
therapy during the first two years after transplantation in 
patients already on statins. Vitamin C (2 × 500 mg/d) and vi-
tamin E (2 × 400 IU/d) reduced the progression of vasculop-
athy measured by IVUS and defined as the change in aver-
age intimal index (plaque area divided by vessel area) after 
one-year of follow-up (103). Improvement in endothelial 
protection by stimulation of the nitric-oxide pathway with 
oral l-arginine may reduce vascular oxidant stress in the 
graft, reverse endothelial dysfunction, and decrease blood 
pressure after transplantation, which may help to prevent 
vasculopathy (104,105). Aggressive CMV prophylaxis in all 
and not only in high-risk transplantation recipients corre-
lated with less intimal thickening on IVUS (106). Interest-
ingly, there is no evidence for benefit from standard anti-
platelet therapy in heart transplant patients. This may be 
explained with high on-treatment platelet reactivity, ie, 
aspirin resistance after transplantation (9).
treAtMent
The treatment of posttransplant vasculopathy is not very 
promising and it primarily modifies immunosuppressive 
regimens. Selected patients may be treated with per-
cutaneous coronary interventions (PCI), while only few 
patients are candidates for coronary artery bypass graft-
ing (CABG). Revascularization procedures are associated 
with poor long-term results and are considered pallia-
tive due to the diffuse and progressive nature of vascu-
lar changes. Heart failure medications should be intro-
duced with the signs of graft failure, while in patients 
with severe disease, the only option remains to be re-
transplantation.
Short-term enhancement of immunosuppressive thera-
py may slow down the progression of CAV (three days of 
methylprednisolone plus antithymocite globulin). This ef-
fect is more pronounced if applied early, ie, within the first 
posttransplant year. However, due to significant risk of in-
fections and malignant diseases, this approach is not ad-
opted in routine practice (107).
There is evidence that both EVL and SRL prevent CAV de-
velopment, but established vasculopathy is treated only 
with SRL (107). A study in which antimetabolites (azathio-
prine or MMF) were replaced with SRL, while CNI and cor-
ticosteroids remained unchanged, showed a better out-
come in patients with severe CAV – combined end-point 
of death, PCI, CABG, myocardial infarction and increase in 
semiquantitative catheterization score (108). However, MIT 
was measured with IVUS only in a minority of patients, in 
whom no difference was found (108).
Raichlin et al replaced CNI with SRL as a primary immu-
nosuppressive drug in patients with vasculopathy and/or 
renal impairment (109). The secondary immunosuppres-
sants (MMF or azathioprine) and corticosteroids were un-
changed. The replacement resulted in stable plaque vol-
ume and plaque index (defined as plaque volume/vessel 
volume), while the CNI group exhibited further progres-
sion of vasculopathy (109). However, the Heart Save the 
Nephron trial was prematurely terminated as 4 of 7 pa-
tients in whom CNI drug was replaced with SRL 12 weeks 
after the heart transplantation experienced grade IIIA re-
jection (110). We recommend caution when SRL is used 
instead of CNI as a primary immunosuppressant during 
the early post-transplant phase before pathohistologi-
cal evidence of durable rejection control in our patient 
is obtained.
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PCI is considered palliative because it does not influence 
the progressive nature of CAV. No studies tested the effect 
of PCI on the graft and patient survival. Optimal candidates 
for PCI are patients with focal and one vessel disease (Fig-
ure 3), who represent only a minority of patients with vas-
culopathy. Drawbacks of PCI in transplant patients include 
diffuse coronary disease, distal vessel pruning, common 
metabolic abnormalities (diabetes, dyslipidemia), the use 
of contrast agents in patients with nephrotoxic immuno-
suppressive therapy and preexistent renal failure, as well as 
high in-stent restenosis (ISR) rate. Although the immediate 
success rate of angioplasty was high (>92%), the restenosis 
rate was up to 55% during the next 15 months (111-115). 
Patients with calcified lesions might require rotablation, 
which has the periprocedural mortality of 18% (116). Com-
pared to plain angioplasty, bare-metal stent (BMS) implan-
tation resulted in higher primary procedural success rate 
and lower restenosis rate at three months (7% vs 39%) as 
well as at eight months (34% vs 71%) (117,118). However, in 
33 patients with CAV there was no difference in restenosis 
rate (68% vs 69%) stenting after 5 years of follow-up (119). 
When compared to BMS, drug-eluting stents (DES) signifi-
cantly reduced the restenosis rate in short and mid-term 
follow-up (≤19 months) (120-123). However, another study 
found no difference in restenosis rate between BMS or DES 
after 5 years of follow-up (124) but DES group had signifi-
cantly higher prevalence of diabetes mellitus, longer time 
from heart transplantation to PCI, as well as a longer mean 
stent length. These factors might have influenced the sus-
ceptibility to stent restenosis and influenced the obtained 
results (124). SRL-eluting stents did not differ from pacli-
taxel-eluting stents with respect to binary restenosis, late 
lumen loss, or incidence of major adverse cardiac events 
after PCI (125). ISR is associated with progressive lumen 
loss in remote coronary lesions and, clinically more im-
portant, it represents a strong independent risk factor for 
future myocardial infarction and mortality in transplanted 
patients (126). The risk of ISR is increased by the presence 
of IgG antibodies to MHC class I antigen increases (127). 
A significant reduction of restenosis rate was achieved by 
treatment with MMF dose of ≥2 × 1.5 g/d (128).
Because of the diffuse nature of transplant vasculopathy 
and high perioperative mortality, surgical revascularization 
is an option in a very small number of patients with CAV. 
Coronary bypass grafting is associated with high periop-
erative mortality (36%) and only few patients with CAV are 
candidates for this type of revascularization (116).
otHer treAtMent MoDALItIeS AnD Future 
StrAteGIeS
According to the present guidelines for SCD prevention 
in heart failure patients, implantable cardioverter defibril-
lators are used for the prevention of SCD in patients with 
severe CAV and reduced systolic function (129). However, 
there are no specific trials on this matter in the transplant 
population. For patients with terminal graft vasculopathy, 
the only definitive treatment is retransplantation. However, 
the survival at 5 years after heart retransplantation is <50%. 
The independent predictors of high mortality include the 
period of less than two years between two transplanta-
tions, the recipient age, intensive care treatment, mechani-
cal ventilation, and the use of ventricular assist device as 
bridge-to-retransplantation (130). In practice, retransplan-
tation is restricted only to highly selected patients, typically 
of young age.
As present CAV prevention and treatment modalities are 
very limited, there is a need for novel strategies. Alloim-
mune response may be prevented by induction of allograft 
tolerance by targeting local or circulating dendritic cells or 
by modulating T-cells co-stimulation pathways (131). Graft 
survival may be prolonged by cell therapy with autolo-
gous interleukin-10-engineered hematopoietic stem cells 
before transplantation, due to anti-inflammatory effect of 
this cytokine (132). Also, CAV in patients with deficient fi-
brinolysis or endothelial dysfunction may be prevented 
by induction of genes for tPA or endothelial nitric-
FIGure 3. Subocclusive left anterior descending artery inci-
dentally detected in an asymptomatic patient with anterior 
wall hypocontractility on routine echocardiographic exam 8 
months after transplantation.
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oxide synthase by means of intracoronary gene transfer 
(133,134). Before more effective preventive and therapeu-
tic strategies are developed, cardiac allograft vasculopa-
thy will remain the most important limitation of long-term 
heart transplant survival.
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